Pregabalin and Duloxetin in fibromyalgia treatment
Not Applicable
- Conditions
- Fibromyalgia.Fibromyalgia
- Registration Number
- IRCT2016030626935N1
- Lead Sponsor
- Vice Chancellor for Research of Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 70
Inclusion Criteria
fibromyalgia patients; age between 18 to 65;
Exclusion criteria: receiving Duloxetine, Pregabalin and Gabapentin with other antidepressants during the 12 weeks before entering the study; pregnancy or have a plan to become pregnant during the study; underlying rheumatic disease, cancer, and other diseases that can cause chronic pain which has not been defined in the fibromyalgia syndrome; having a job or duties which need high concentration or alertness; use of MAOI (monoamine oxidase inhibitors) within 14 days before study; chronic liver disease, severe renal failure and uncontrolled narrow-angle glaucoma; history of hypersensitivity to Pregabalin and its components
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pain. Timepoint: At the begining and 4 weeks after treatment. Method of measurement: FIQ and WPI questionaire.;Depression. Timepoint: At the begining and 4 weeks after treatment. Method of measurement: SF-12 and becks questionaire.
- Secondary Outcome Measures
Name Time Method Drug adverse reactions. Timepoint: 1 week after start the drug. Method of measurement: Drug adverse reactions questionnaire.